NeuroPace Q4 Earnings Call Highlights [Yahoo! Finance]
Neuropace, Inc. (NPCE)
Company Research
Source: Yahoo! Finance
System sales (RNS up 26% in Q4 and 25% for the year), with adjusted EBITDA positive $0.9M —the second consecutive quarter—and ending the year with $61.1M in cash. For 2026 the company reiterated revenue guidance of $98–100M on a continuing-operations basis (implying ~20–22% underlying RNS growth), will report adjusted operating metrics excluding DIXI and stock comp, and expects adjusted operating expense of $90–92M and adjusted EBITDA loss of $9–10M Regulatory/product progress includes FDA acceptance of the PMA supplement to expand RNS into idiopathic generalized epilepsy (180-day review clock; prior data showed a 77% median seizure reduction), and the AI-enabled SeizureID plus cloud clinician platform is expected to be approved in H1 2026 , with remote-care and pediatric expansion efforts underway. Interested in NeuroPace, Inc.? Here are five stocks we like better. NeuroPace (NASDAQ:NPCE) reported fourth-quarter and full-year 2025 results that management said reflected sustai
Show less
Read more
Impact Snapshot
Event Time:
NPCE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NPCE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NPCE alerts
High impacting Neuropace, Inc. news events
Weekly update
A roundup of the hottest topics
NPCE
News
- NeuroPace to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness Wire
- How Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment Narrative [Yahoo! Finance]Yahoo! Finance
- NeuroPace (NPCE) was upgraded by Wells Fargo & Company to "strong-buy".MarketBeat
- How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions [Yahoo! Finance]Yahoo! Finance
- NeuroPace (NPCE) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NPCE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "buy" to "holMarketBeat
NPCE
Earnings
- 3/3/26 - Beat
NPCE
Sec Filings
- 3/25/26 - Form 4
- 3/24/26 - Form 4
- 3/24/26 - Form 4
- NPCE's page on the SEC website